Biopharma

Abstract Pediatric drug delivery presents unique challenges due to physiological and pharmacological differences across age groups, requiring specialized formulation approaches...

Abstract Small interfering RNA (siRNA)-loaded lipid nanoparticles (LNPs) are a promising modality for gene silencing therapies. Pulmonary delivery offers an...

Abstract Background: Despite the growing importance of polypeptide-based drugs in clinical therapy, studies investigating the stability of their freeze-dried formulations...

Abstract High dose biologic drug products (DPs) have become a common trend for the treatment of chronic diseases across a...

Abstract Background In the current era of the global increase in autoimmune and inflammatory disorders, predominantly rheumatoid arthritis (RA), there...

Abstract During the pandemic, lipid nanoparticles (LNPs) became widely established as RNA nanocarriers, and hold the promise of future targeting...

World’s First Mass Production Through Enzyme Innovation Trehalose (α-D-glucopyranosyl α-D-glucopyranoside) is a naturally occurring disaccharide prized for its ability to...

Abstract Formulation development of protein biopharmaceuticals has become increasingly challenging due to new modalities and higher target drug substance concentrations....

CPhI Frankfurt and AAPS PharmSci 360 Review Ashland showed multiple new and optimized pharmaceutical product offerings during CPHI Frankfurt and...

Abstract Cyclodextrins (CDs) have traditionally been recognized as excipients that enhance solubility and stability of drugs. However, growing evidence shows...